Introduction

Molecular Medicine Reports

1791-2997 1791-3004

D.A. Spandidos

10.3892/mmr.2017.6931

mmr-16-03-2700

Articles

Salidroside protects PC12 cells from Aβ_1–40-induced cytotoxicity by regulating the nicotinamide phosphoribosyltransferase signaling pathway

Huang

Xujiao

Xing

Sanli

Chen

Chuan

Zhihua

Chen

Jiulin

Geriatrics Laboratory, Shanghai Geriatric Institute of Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200031, P.R. China

Correspondence to: Dr Sanli Xing or Dr Chuan Chen, Geriatrics Laboratory, Shanghai Geriatric Institute of Chinese Medicine, Shanghai University of Traditional Chinese Medicine, 365C South Xiangyang Road, Shanghai 200031, P.R. China, E-mail: xingsanli@163.com, E-mail: article_chenchuan@163.com

032017

05072017

16 3 2700 2706 19082016 12052017

2017

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Alzheimer's disease (AD) is the most common type of senile dementia, which often develops in elderly or presenile individuals. As one of the pathological features of AD, amyloid β-protein (Aβ) causes energy dysmetabolism, thereby inducing cellular damage and apoptosis. Salidroside is the main active component of the traditional Chinese medicine Rhodiola. Previous studies have demonstrated that salidroside exerts a regulatory role in energy metabolism. However, the role and the mechanism of action of salidroside in AD remain unclear. Therefore, the present study used Aβ1–40 to induce damage in PC12 cells, thereby establishing a cell model of AD. In addition, salidroside treatment was performed to investigate the protective effect of salidroside and the underlying mechanisms. Aβ1-40-induced neuronal toxicity reduced cell viability and caused cellular damage. As a result, the expression level of nicotinamide phosphoribosyltransferase (NAMPT) decreased, the synthesis of nicotinamide adenine dinucleotide (NAD⁺; an energy metabolism-associated coenzyme) became insufficient, and the NAD⁺/nicotinamide adenine dinucleotide hydride ratio was reduced. Administration of salidroside alleviated Aβ-induced cell damage and increased the expression level of the key protein NAMPT and the synthesis of NAD⁺. The results of the present study demonstrate that salidroside exerts a protective effect on Aβ1-40-damaged PC12 cells. The underlying mechanism may be associated with the regulation of energy metabolism that relies predominantly on the NAMPT signaling pathway.

Alzheimer's disease salidroside amyloid β-protein_1–40 nicotinamide phosphoribosyltransferase nicotinamide adenine dinucleotide

Introduction

Alzheimer's disease (AD) is the most common form of dementia that affected an estimated 44 million individuals in 2015. This figure is expected to increase to 135 million by the year 2050 throughout the world (1). The main clinical symptoms of AD include memory impairment, decreased self-care ability, aphasia and visuospatial dysgnosia (2). Neuropathological studies have confirmed that extracellular senile plaque deposition, intracellular accumulation of neurofibrillary tangles and neuronal degeneration loss are the main pathological hallmarks of AD (3,4). Deposition of amyloid β-protein (Aβ) in the brain leads to the formation of senile plaques, which represent a primary pathological characteristic of AD (5). Aβ refers to a class of amyloid precursor protein (APP)-derived polypeptides that are formed under the action of β- and γ-secretase. The common subtypes of Aβ are Aβ_1–40 and Aβ_1–42, and each exert neurotoxic effects and induce apoptosis. Therefore, reducing Aβ-induced neuron injury and intervening in AD progression are critical for the treatment of AD.

Studies have shown that energy dysmetabolism contributes significantly to the pathogenesis of a variety of ageing-associated diseases and degenerative diseases of the nervous system, including AD (6). Homeostatic imbalance of energy metabolism develops gradually in the brain with age, which promotes Aβ production. Aβ further induces energy dysmetabolism in the brain, resulting in impaired neuronal synaptic function (7,8). Nicotinamide adenine dinucleotide (NAD⁺) is an important coenzyme in the in vivo redox reaction. It participates in energy synthesis through glycolysis, the tricarboxylic acid cycle and mitochondrial oxidative phosphorylation (9). NAD⁺ may be synthesized de novo, although the majority of NAD is synthesized via the salvage pathway from the conversion of nicotinamide into nicotinamide mononucleotide, which is later converted to NAD⁺ (10). The NAD⁺/nicotinamide adenine dinucleotide hydride (NADH) ratio is a fundamental indicator of the cellular redox status (11). Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in the NAD⁺ salvage pathway, and it has been demonstrated that NAMPT participates in energy metabolism and maintains the homeostasis of energy metabolism in the brain by regulating NAD⁺ synthesis; thus, increased expression levels of NAMPT have been shown to positively regulate NAD⁺ levels (12). Knockout of the NAMPT gene enhances the formation of Aβ plaques in the brain (13). Therefore, recent studies have focused on regulation of NAMPT expression for the purpose of protecting against AD and other neurodegenerative diseases (13–15).

Rhodiola rosea is a perennial herb that belongs to the family Crassulaceae and genus Rhodiola. Rhodiola is a traditional herbal medicine commonly used across Asia and grows at altitudes of 1,800–2,500 m in cold, pollution-free zones. Rhodiola stimulates the nervous system, improves work efficiency, alleviates fatigue and prevents mountain sickness. Salidroside is the primary active ingredient of Rhodiola. Various studies have shown that salidroside inhibits the inflammatory response (16), reduces oxidative stress-induced damage (17) and exerts an anticancer effect (18). Certain studies demonstrated that salidroside has a neuroprotective effect, for example, salidroside inhibited Aβ-induced neurotoxicity by regulating the phosphatidylinositol 3-kinase/Akt signaling pathway in primary cultured neurons (19). In a rat model of AD, salidroside improved memory impairment of rats (20), and salidroside reduced mitochondrial swelling and attenuated the injury in the central nervous system (21). However, whether the neuroprotective effects of salidroside involve regulation of the NAMPT/NAD⁺ signaling pathway in PC12 cells remains unknown.

To gain further insights into the neuroprotective functions of salidroside, a PC12 model was used in the present study and the underlying mechanisms were investigated. Whether the neuroprotective effects of salidroside increasing NAD levels against Aβ_1–40-induced neurotoxicity in PC12 cells were elucidated in the current study. Furthermore, the possible underlying mechanisms were examined by investigating NAMPT expression levels.

Materials and methods <sec> <title>Preparation of Aβ1–40

The lyophilized powder of Aβ1–40 (cat no. A1075; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was diluted with sterile distilled water to a concentration of 200 µmol/l. Subsequently, Aβ1–40 was incubated at 37°C for 7 days and stored at 4°C for further assays.

Cell culture and treatment

Highly differentiated PC12 rat adrenal pheochromocytoma cells (Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China) were maintained in Dulbecco's modified Eagle's medium (DMEM; cat no. 12100046) containing Gibco 10% fetal bovine serum (cat no. 10099-141) (both from Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% penicillin-streptomycin. The cells were maintained in a 37°C incubator in an atmosphere of 5% CO₂ and grew adherently. The culture medium was replaced daily. Upon reaching 80–90% confluence, the cells were trypsinized for 1–2 min. Once the cells became round, 2 ml of culture medium was added to the cells. The cells were then centrifuged, 1,500 × g for 5 min at room temperature, resuspended, and split into culture dishes. The cells were divided into the following main groups: Normal control group, the Aβ1–40 group, the Aβ1–40 + salidroside (cat no. B20504; Shanghai Yuanye Biological Technology Co., Ltd., Shanghai, China) group, and the salidroside group. The normal control group was cultured conventionally in DMEM and did not receive any treatment. The Aβ1–40 group was subjected to 24 h of treatment with 5 µmol/l Aβ1-40. The Aβ1–40 + salidroside group was subjected to simultaneous Aβ1–40 (5 µmol/l) and salidroside (100 µmol/l) treatments for 24 h. The salidroside group was treated with 100 µmol/l salidroside for 24 h.

Cell viability assay

PC12 cells were seeded into 96-well plates and cultured at 37°C in DMEM for 24 h. Once the cells attached stably to the culture surface, various concentrations of Aβ1–40 (1, 5 or 10 µmol/l) or salidroside (12.5, 25, 50, 100 or 200 µmol/l) were added to the cells. Following a 24-h treatment, each well of cells was overlaid with 10 µl MTT solution (5 mg/ml; cat no. C0009) obtained from Beyotime Institute of Biotechnology (Haimen, China) and incubated at 37°C for 4 h. The supernatant was discarded, and 150 µl dimethyl sulphoxide was added to each well of cells to fully dissolve the crystals. Subsequently, absorbance was measured at a wavelength of 490 nm using a PowerWave XS microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).

Lactate dehydrogenase (LDH) activity assay

The cells were subjected to different treatments (medium only, 5 µmol/l Aβ1-40, 5 µmol/l Aβ1–40 + 100 µmol/l salidroside or 100 µmol/l salidroside). Subsequently, the activity of released LDH was examined according to the instructions provided with the LDH Activity Assay kit (cat. no. G1780; Promega Corporation, Madison, WI, USA). Absorbance was measured at a wavelength of 490 nm. The LDH release was expressed as a percentage relative to the positive control group.

NAD+/NADH analysis

An NAD⁺/NADH quantification kit was used to determine NAD⁺ and NADH levels (cat no. k337-100; BioVision, Inc., Milpitas, CA, USA) according to the manufacturer's instructions. The cells were washed with pre-cooled phosphate-buffered saline (PBS), homogenized in 400 µl NAD⁺/NADH extraction buffer, and then centrifuged for 5 min at 18,000 × g and 4°C. The resulting supernatants were transferred to fresh Eppendorf (EP) tubes and labelled as NADt samples. Subsequently, 200 µl NADt sample was transferred to fresh EP tubes and heated at 60°C for 30 min (all NAD⁺ decomposed, leaving only NADH to be analyzed). After cooling on ice, the samples were quickly centrifuged 12,000 × g for 30 sec at 4°C, and the resulting pellets were discarded. The supernatants were collected and labelled as NADH samples for further assays. Standards (0, 2, 4, 6, 8 and 10 µl) and 40 µl samples were loaded into the wells of a microtiter plate, and appropriate volumes of NAD⁺/NADH Extraction Buffer were added to bring the volume to 50 µl. Subsequently, 100 µl enzyme reaction mix and 10 µl NADH developer were added to each well. The mixtures were allowed to react at room temperature (RT) for 1–4 h, and the absorbance was measured using a microplate reader (wavelength, 450 nm).

Immunofluorescence assay

Following various treatments and interventions, all groups of cells were washed with PBS for 5 min. The cells were then fixed with 4% paraformaldehyde for 15 min, blocked with a blocking solution containing 10% calf serum for 45 min at RT, incubated with anti-NAMPT antibody (dilution, 1:200; cat no. ab45890; Abcam, Cambridge, MA, USA) at 37°C for 1 h, and placed in a 4°C refrigerator overnight. After washing with PBS, the cells were incubated with fluorescein isothiocyanate-labelled goat anti-rabbit IgG (dilution, 1:500; cat no. A0562; Beyotime Institute of Biotechnology) for 1 h in a 37°C incubator. After 3 rinses with PBS, the cells were covered with DAPI staining solution (cat no. C1005; Beyotime Institute of Biotechnology) and incubated at RT for 5 min. The cells were rinsed 3 more times with PBS (5 min each time). Subsequently, the cells were mounted onto glass slides in PBS and glycerol (1:1). The fluorescence signal was examined using an Olympus BX51 biological microscope at a magnification of ×200.

Western blot analysis

At the end of the treatment period, all groups of cells were collected. Following centrifugation 1,500 × g for 5 min at RT, the cells were lysed in lysis buffer. The resulting supernatants were extracted and the protein concentrations in the supernatants were determined using the bicinchoninic acid (BCA) method. Subsequently, the supernatants were mixed thoroughly with 5X sodium dodecyl sulphate (SDS) loading buffer, boiled at 100°C for 5 min, cooled on ice and then stored at −20°C. Immediately before the experiments, the protein samples were thawed at RT. The protein samples (50 µg each) were heated at 95°C for 5 min, then separated by SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. The membranes were blocked with 2% bovine serum albumin for 1 h and then incubated with the primary antibody (anti-NAMPT antibody, dilution, 1:250; cat no. ab45890; Abcam) at 4°C overnight. Subsequently, the membranes were washed with PBS for 45 min, incubated with horseradish peroxidase-labelled secondary antibody (dilution, 1:2,000; cat no. SA00001-2; ProteinTech Group, Inc., Chicago IL, USA) at 37°C for 1 h, and washed again in PBS for 45 min. Protein bands were examined using an ImageQuant LAS 4000 mini chemiluminescence detector (GE Healthcare Life Sciences, Little Chalfont, UK). GAPDH (dilution, 1:1,000, cat no. 5174S; Cell Signaling Technology, Inc., Danvers, MA, USA) served as a loading control.

Statistical analysis

The results were statistically analyzed using GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA). All data are expressed as the mean ± standard error. One-way analysis of variance was used to assess multiple groups of data and Student's t-test was used to compare between two groups and P<0.05 was considered to indicate a statistically significant difference.

Results <sec> <title>Impact of Aβ1–40 treatment on the viability of PC12 cells and the protective effect of salidroside

PC12 cells were treated with various concentrations of Aβ1–40 (1, 5 or 10 µmol/l) for 24 h, which enabled the analysis of changes in PC12 cell viability under the action of different concentrations of Aβ1-40. The results demonstrated that cell viability declined as the Aβ1–40 concentration increased. The viability of PC12 cells decreased by ~15% after treatment with 5 µmol/l Aβ1-40. Therefore, a concentration of 5 µmol/l Aβ1–40 was selected to establish the cell model of AD (Fig. 1A).

Before investigation of the protective effect of salidroside, the present study first examined whether salidroside would exert a neurotoxic effect on normal PC12 cells at certain concentrations. PC12 cells were treated with various concentrations of salidroside (12.5, 25, 50, 100 or 200 µmol/l). Compared with the normal control group, 24-h incubation with 12.5, 25 or 200 µmol/l salidroside exerted no significant effect on normal PC12 cells, whereas incubation with 50 and 100 µmol/l salidroside improved cell viability (P<0.05). Therefore, the two concentrations of salidroside (50 and 100 µmol/l) were selected for further investigation of the effect of salidroside on the viability of PC12 cells that were damaged by Aβ_1–40 exposure. The results indicated that cell viability was significantly decreased in the Aβ_1–40 group compared with the normal control group (P<0.01). Compared with the Aβ_1–40 group, treatment with 50 µmol/l salidroside failed to significantly improve the viability of Aβ_1–40-damaged cells, whereas treatment with 100 µmol/l salidroside improved the viability of cells damaged by Aβ_1–40 (P<0.05). The results demonstrated that 100 µmol/l salidroside exerted an effect on cell viability and alleviated the Aβ-induced PC12 cell injury. Therefore, this salidroside concentration (100 µmol/l) was selected for further experiments (Fig. 1B).

Salidroside reduces the LDH level of Aβ1–40-treated cells

The LDH level of a culture supernatant indirectly reflects the effects of Aβ1–40 and salidroside on cells. As shown in Fig. 2, the Aβ1–40 group displayed a significantly increased LDH level compared with that of the normal control group (P<0.01). By contrast, the LDH level was markedly reduced in the Aβ1–40 + salidroside group compared with the Aβ1–40 group (P<0.05). The results demonstrated that salidroside reduced the Aβ1-40-induced cellular damage.

Salidroside increases the NAD+ level and NAD+/NADH ratio of Aβ1–40-treated cells

NAD⁺ and NADH are coenzymes that are necessary for cellular energy metabolism. Under normal physiological conditions, the NAD⁺/NADH ratio reflects the cellular redox status and is in a constant state of dynamic equilibrium. Disorders of cellular energy metabolism are characterized by changes in NAD⁺ and NADH levels, and an imbalance in the NAD⁺/NADH ratio (22). In the present study, the Aβ1–40 group exhibited a decreased level of NAD⁺ compared with that of the normal control group (P<0.01; Fig. 3A). However, the NADH level did not change significantly in the Aβ1–40 group compared with the normal control group (Fig. 3B). As a result, the NAD⁺/NADH ratio was reduced in the Aβ1–40 group (P<0.01; Fig. 3C). No significant difference was identified in the NADH level between the Aβ1–40 + salidroside group and the Aβ1–40 group (Fig. 3B). By contrast, the Aβ1–40 + salidroside group demonstrated a significant increase in the NAD⁺ level (P<0.05; Fig. 3A) and the NAD⁺/NADH ratio (P<0.05; Fig. 3C).

Salidroside upregulates the expression level of NAMPT

NAMPT is the rate-limiting enzyme in the salvage pathway of NAD⁺ biosynthesis and is important in regulating the homeostasis of energy metabolism. The results of an immunofluorescence assay demonstrated that the NAMPT-derived fluorescence signal was reduced following 24 h of Aβ1–40 treatment, whereas salidroside treatment increased the NAMPT fluorescence signal (Fig. 4A and B). In addition, western blot analysis demonstrated that NAMPT expression was decreased in the Aβ1–40 group compared with the normal control group. Salidroside treatment significantly increased the expression level of NAMPT (Fig. 4C and D). Thus, the results indicate that salidroside regulates NAMPT protein expression.

Discussion

AD is the most common cause of dementia in the elderly, but the exact pathogenetic mechanisms underlying AD remain uncertain. In previous studies, one extensively investigated mechanism is Aβ-mediated neurotoxicity; the aggregates of Aβ peptides exhibit cytotoxicity in vivo and in vitro (23). Aβ_1–40 and Aβ_1–42 are two major forms of Aβ, although Aβ_1–42 is markedly more prone to aggregation and more toxic to neurons than Aβ_1–40; however, Aβ_1–40 was the predominant isoform of the most abundant cleaved form of APP (~90%) and exerts a toxic effect on neurons in the AD brain (24). In addition, the deposition of Aβ_1–40 is required for the development of mature amyloid plaques from the initial deposition of Aβ_1–42, which was regarded as an early pathological process of AD, and Aβ_1–40 is often used to establish the model of AD in vivo and in vitro (25). Injecting 5 mg/ml Aβ_1–40 caused hippocampal neuronal loss or functional impairment and is thus considered as an indication of energy metabolism (26). As Aβ_1–40 possesses neuronal toxicity and is capable of inducing neuronal neurotoxicity, PC12 cells treated with Aβ_1–40 were used as the cell model of AD in the current study. The neuronal toxicity of Aβ_1–40 is reflected in its ability to cause energy dysmetabolism, and induce cell damage and death (27,28). A number of previous studies used PC12 cells to investigate the molecular mechanisms underlying the development of degenerative diseases of the nervous system (29–32). Therefore, the present study employed the PC12 cells that were damaged by Aβ_1–40 exposure as the cell model of AD and the significance of NAMPT in AD was evaluated.

The present study demonstrated that Aβ_1–40 treatment reduced the NAD⁺ expression level. The underlying reason may be associated with decreased NAMPT expression. As the rate-limiting enzyme in the NAD⁺ salvage pathway, NAMPT promotes the production of NAD⁺ (33). Previous studies demonstrated that an elevated NAMPT level reduces cell death (34,35), which is consistent with the results of the present study, which indicate that salidroside increased NAMPT expression and improved cell survival. In addition, the present study identified that salidroside significantly reduced the level of LDH released when compared with that in the Aβ_1–40 group. The results of the LDH assay were consistent with those of the MTT assay, demonstrating that salidroside treatment attenuated the Aβ_1–40-induced PC12 cell injury and exerted a protective effect on PC12 cells.

The expression level of Aβ increases as AD progresses, which causes mitochondrial dysfunction and energy metabolism disorders. The elevated Aβ expression level represents one of the reasons behind neuronal damage and apoptosis (36). NAD⁺ participates in energy metabolism. Furthermore, loss of NAD⁺ homeostasis leads to decreased sirtuin-1 (SIRT1) activity. Consequently, SIRT1-mediated deacetylation of signaling molecules (including transcription factors and enzymes) is reduced (37,38). Peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) is a coactivator of the nuclear hormone receptor peroxisome proliferator-activated receptor γ, which also undergoes SIRT1-mediated deacetylation and participates in mitochondrial biosynthesis and energy homeostasis (39). The decreased SIRT1 activity in the brain affects the function of the downstream protein PGC-1α in energy synthesis, resulting in a brain energy crisis (40). As NAMPT is important in NAD⁺ synthesis, the present study investigated whether salidroside exerts its regulatory effect on energy metabolism pathways via NAMPT. Namely, salidroside attenuates the neuronal toxicity of Aβ by further regulating NAD⁺/NADH levels. Studies have demonstrated that the expression level of NAMPT decreases gradually with age, with the decrease in NAMPT level particularly evident in the brain of AD mice compared with aged healthy mice. Such a decrease exacerbates neuronal apoptosis (34,41,42). By contrast, increased NAMPT expression levels in the hippocampus and cortex improve cognitive function (35). Therefore, novel treatment strategies for AD may involve the administration of salidroside to regulate NAMPT expression and reduce the severity of AD.

The present study demonstrated that salidroside exerted a protective effect on PC12 cells damaged by Aβ_1–40 exposure. An AD model was established by Aβ_1–40 treatment. The viability of PC12 cells decreased and the level of LDH release significantly increased. In addition, the protein expression of NAMPT, the level of NAD⁺ and the ratio of NAD⁺/NADH were decreased. The above-mentioned effects of Aβ_1–40 were attenuated following salidroside treatment. In addition, the present study demonstrated that the decrease in NAMPT/NAD⁺ levels may represent one of the molecular pathological mechanisms of AD.

In conclusion, the present study demonstrated that salidroside exerted a protective effect on PC12 damaged by Aβ_1–40 treatment. The protective effect of salidroside may reside in its regulatory effect in energy metabolism, such as the increases in NAMPT expression levels and NAD⁺ production. Therefore, NAMPT and NAD⁺ are considered to be key factors in AD, as well as other neurodegenerative diseases. Thus, regulation of NAMPT and NAD⁺ may serve as novel therapeutic strategies for the treatment of AD.

Acknowledgements

The present study was supported by grants from the National Natural Science Foundation of China (grant no. 81503626) and the Shanghai Health Bureau Youth Fund (grant nos. 201540254 and 20134331).

References 1

Van Cauwenberghe

Van Broeckhoven

Sleegers

The genetic landscape of Alzheimer disease: Clinical implications and perspectives

Genet Med184214302016

10.1038/gim.2015.117

26312828

Scheltens

Blennow

Breteler

de Strooper

Frisoni

Salloway

Van der Flier

Alzheimer's disease

Lancet3885055172016

10.1016/S0140-6736(15)01124-1

26921134

Perl

Neuropathology of Alzheimer's disease

Mt Sinai J Med7732422010

10.1002/msj.20157

20101720

2918894

Serrano-Pozo

Frosch

Masliah

Hyman

Neuropathological alterations in Alzheimer disease

Cold Spring Harb Perspect Med1a0061892011

10.1101/cshperspect.a006189

22229116

3234452

Sadigh-Eteghad

Sabermarouf

Majdi

Talebi

Farhoudi

Mahmoudi

Amyloid-beta: A crucial factor in Alzheimer's disease

Med Princ Pract241102015

10.1159/000369101

25471398

Yin

Boveris

Cadenas

Mitochondrial energy metabolism and redox signaling in brain aging and neurodegeneration

Antioxid Redox Signal203533712014

10.1089/ars.2012.4774

22793257

3887431

Wang

Diao

Kwak

Liu

Zhi

Büeler

Bhat

Williams

Park

Liao

Metabolic stress modulates Alzheimer's β-secretase gene transcription via SIRT1-PPARγ-PGC-1 in neurons

Cell Metab176856942013

10.1016/j.cmet.2013.03.016

23663737

5396538

Yin

Hwang

Tang

Yang

NAD attenuates oxidative DNA damages induced by amyloid beta-peptide in primary rat cortical neurons

Free Radic Res487948052014

10.3109/10715762.2014.907889

24678962

Ussher

Jaswal

Lopaschuk

Pyridine nucleotide regulation of cardiac intermediary metabolism

Circ Res1116286412012

10.1161/CIRCRESAHA.111.246371

22904042

Rongvaux

Shea

Mulks

Gigot

Urbain

Leo

Andris

Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis

Eur J Immunol32322532342002

10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L

12555668

Ying

NAD⁺/NADH and NADP⁺/NADPH in cellular functions and cell death: Regulation and biological consequences

Antioxid Redox Signal101792062008

10.1089/ars.2007.1672

18020963

Revollo

Grimm

Imai

The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals

Curr Opin Gastroenterol231641702007

10.1097/MOG.0b013e32801b3c8f

17268245

Villela

Schlesinger

Suemoto

Grinberg

Rosenberg

A microdeletion in Alzheimer's disease disrupts NAMPT gene

J Genet935355372014

10.1007/s12041-014-0399-3

25189255

Imai

Guarente

NAD⁺ and sirtuins in aging and disease

Trends Cell Biol244644712014

10.1016/j.tcb.2014.04.002

24786309

4112140

Herrera-Arozamena

Martí-Marí

Estrada

de la Fuente Revenga

Rodríguez-Franco

Recent advances in neurogenic small molecules as innovative treatments for neurodegenerative diseases

Molecules21pii: E11652016

10.3390/molecules21091165

27598108

Ling

Feng

Salidroside attenuates inflammatory response via suppressing JAK2-STAT3 pathway activation and preventing STAT3 transfer into nucleus

Int Immunopharmacol352652712016

10.1016/j.intimp.2016.04.004

27085677

Yang

Wang

Zuo

Guan

Dai

Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats

BMC Pharmacol Toxicol17162016

10.1186/s40360-016-0059-8

27075663

4831194

Sun

Xia

Anticancer effect of salidroside on colon cancer through inhibiting JAK2/STAT3 signaling pathway

Int J Clin Exp Pathol86156212015

25755753

4348934

Zhang

Wang

Xiong

Zhao

Chu

Sun

Chen

Neuroprotective effects of salidroside through PI3K/Akt pathway activation in Alzheimer's disease models

Drug Des Devel Ther10133513432016

27103787

4827895

Gao

Zhou

You

Luo

Chang

Zhu

Ding

Yan

Salidroside suppresses inflammation in a D-galactose-induced rat model of Alzheimer's disease via SIRT1/NF-κB pathway

Metab Brain Dis317717782016

10.1007/s11011-016-9813-2

26909502

Zhang

Peng

Yang

Xiao

Song

Lin

Protective effects of salidroside on mitochondrial functions against exertional heat stroke-induced organ damage in the rat

Evid Based Complement Alternat Med20155045672015

10.1155/2015/504567

26664452

4667077

Yang

Sauve

NAD⁺ metabolism: Bioenergetics, signaling and manipulation for therapy

Biochim Biophys Acta1864178718002016

10.1016/j.bbapap.2016.06.014

27374990

Selkoe

Schenk

Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics

Annu Rev Pharmacol Toxicol435455842003

10.1146/annurev.pharmtox.43.100901.140248

12415125

Cheng

Wang

Lin

Huang

Zhang

Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ_25–35 or Aβ_1–40 peptide in rats

Psychopharmacology (Berl)2121811912010

10.1007/s00213-010-1943-3

20640406

Miguel-Hidalgo

Cacabelos

Beta-amyloid(1–40)-induced neurodegeneration in the rat hippocampal neurons of the CA1 subfield

Acta Neuropathol954554651998

10.1007/s004010050825

9600591

Yue

Shanbin

Ling

Yuan

Ying

Ping

Sevoflurane aggregates cognitive dysfunction and hippocampal oxidative stress induced by β-amyloid in rats

Life Sci1431942012015

10.1016/j.lfs.2015.11.002

26551432

Cao

Che

Yang

Xiao

Liu

Inhibitory effects of edaravone in β-amyloid-induced neurotoxicity in rats

Biomed Res Int20143703682014

10.1155/2014/370368

24804216

3996961

Carrillo-Mora

Luna

Colín-Barenque

Amyloid beta: Multiple mechanisms of toxicity and only some protective effects?

Oxid Med Cell Longev20147953752014

10.1155/2014/795375

24683437

3941171

Han

Cheng

Chen

Fang

Wang

7,8-Dihydroxyflavone protects PC12 cells against 6-hydroxydopamine-induced cell death through modulating PI3K/Akt and JNK pathways

Neurosci Lett58185882014

10.1016/j.neulet.2014.08.016

25139527

Guo

Shen

Jin

Ren

Xing

Leptin-Sensitive JAK2 activation in the regulation of Tau phosphorylation in PC12 cells

Neurosignals2488942016

10.1159/000442615

27603322

Chen

Tsai

Chen

Pan

Centella asiatica extract protects against amyloid β1-40-induced neurotoxicity in neuronal cells by activating the antioxidative defence system

J Tradit Complement Med63623692015

10.1016/j.jtcme.2015.07.002

27774420

5067859

Qian

Liu

Yao

Wang

Yang

Wei

Shen

Chen

Caspase-8 mediates amyloid-β-induced apoptosis in differentiated PC12 cells

J Mol Neurosci564914992015

10.1007/s12031-015-0498-5

25645683

Jieyu

Chao

Mengjun

Shalong

Xiaomei

Jianfeng

Zhihong

Nampt/Visfatin/PBEF: A functionally multi-faceted protein with a pivotal role in malignant tumors

Curr Pharm Des18612361322012

10.2174/138161212803582531

22934941

Ghosh

Levault

Brewer

Relative importance of redox buffers GSH and NAD(P)H in age-related neurodegeneration and Alzheimer disease-like mouse neurons

Aging Cell136316402014

10.1111/acel.12216

24655393

4116450

Stein

Wozniak

Dearborn

Kubota

Apte

Izumi

Zorumski

Imai

Expression of Nampt in hippocampal and cortical excitatory neurons is critical for cognitive function

J Neurosci34580058152014

10.1523/JNEUROSCI.4730-13.2014

24760840

3996209

Cabezas-Opazo

Vergara-Pulgar

Pérez

Jara

Osorio-Fuentealba

Quintanilla

Mitochondrial dysfunction contributes to the pathogenesis of Alzheimer's disease

Oxid Med Cell Longev20155096542015

10.1155/2015/509654

26221414

4499633

Zhu

Lee

Ugurbil

Chen

In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences

Proc Natl Acad Sci USA112287628812015

10.1073/pnas.1417921112

25730862

4352772

Wang

Molecular links between caloric restriction and Sir2/SIRT1 activation

Diabetes Metab J383213292014

10.4093/dmj.2014.38.5.321

25349818

4209345

Rodgers

Lerin

Gerhart-Hines

Puigserver

Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways

FEBS Lett58246532008

10.1016/j.febslet.2007.11.034

18036349

Katsouri

Parr

Bogdanovic

Willem

Sastre

PPARγ co-activator-1α (PGC-1α) reduces amyloid-β generation through a PPARγ-dependent mechanism

J Alzheimers Dis251511622011

21358044

Yoshino

Mills

Yoon

Imai

Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice

Cell Metab145285362011

10.1016/j.cmet.2011.08.014

21982712

3204926

Ghosh

LeVault

Barnett

Brewer

A reversible early oxidized redox state that precedes macromolecular ROS damage in aging nontransgenic and 3xTg-AD mouse neurons

J Neurosci32582158322012

10.1523/JNEUROSCI.6192-11.2012

22539844

3376759

Figure 1.

Impact of Aβ_1–40 treatment on the viability of PC12 cells and the effect of salidroside. (A) Effect of the cytotoxicity of Aβ_1–40 on PC12 cell viability. PC12 cells were treated with various concentrations of Aβ_1–40 (1, 5 and 10 µmol/l) for 24 h. (B) Effects of salidroside treatment on the viability of PC12 cells. PC12 cells were treated with various concentrations of salidroside (12.5, 25, 50, 100 and 200 µmol/l) for 24 h, and with different concentrations of salidroside (0, 50, and 100 µmol/l) and exposed to Aβ simultaneously. All data are expressed as the mean ± standard error from four independent experiments. *P<0.05 and **P<0.01 vs. control group; ^#P<0.05 vs. Aβ_1–40 group. Aβ, amyloid β-protein.

Figure 2.

Effect of salidroside treatment on the LDH level of Aβ_1–40-treated cells. PC12 cells were subjected to different treatments (medium only, 5 µmol/l Aβ_1–40, 5 µmol/l Aβ_1–40 + 100 µmol/l salidroside, and 100 µmol/l salidroside) for 24 h. Subsequently, the cells were examined using an LDH Activity Assay kit. All data are presented as the mean ± standard error from four independent experiments (n=4). **P<0.01 vs. control group. ^#P<0.05 vs. Aβ_1–40 group. LDH, lactate dehydrogenase; Aβ, amyloid β-protein; Con, control.

Figure 3.

Effect of salidroside treatment on the NAD⁺ level and NAD⁺/NADH ratio of Aβ_1–40-treated PC12 cells. (A) Effect of salidroside treatment on the NAD⁺ level in the PC12 cells damaged by Aβ_1–40 exposure. (B) Effect of salidroside treatment on the NADH level in the PC12 cells. (C) Effect of salidroside treatment on the NAD⁺/NADH ratio in Aβ_1–40-induced damaged PC12 cells. All data are expressed as the mean ± standard error from four independent experiments (n=4). **P<0.01 vs. control group. ^#P<0.05 and ^##P<0.01 vs. Aβ_1–40 group. NAD⁺, nicotinamide adenine dinucleotide; NADH, nicotinamide adenine dinucleotide hydride; Aβ, amyloid β-protein; Con, control.

Figure 4.

Salidroside upregulates the expression level of NAMPT. (A) NAMPT were detected by immunofluorescence staining and a representative photomicrograph is presented (scale bar, 10 µm). (B) The fluorescence intensity of the NAMPT protein. All data are expressed as the mean ± standard error from three independent experiments. **P<0.01 vs. control group. ^#P<0.05 vs. Aβ_1–40 group. (C) Western blot analyses of PC12 lysates from the control (without any treatment), Aβ_1–40 (with 5 µmol/l Aβ_1–40 treatment), Aβ_1–40 + salidroside (5 µmol/l Aβ_1–40 and 100 µmol/l salidroside simultaneously) and salidroside (100 µmol/l salidroside only) groups. (D) Quantitation of NAMPT protein expression levels. Data are presented as the mean ± standard error of three independent experiments. **P<0.01 vs. control group. ^##P<0.01 vs. Aβ_1–40 group. NAMPT, nicotinamide phosphoribosyltransferase; Aβ, amyloid β-protein; Con, control.